477 related articles for article (PubMed ID: 31402295)
1. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
2. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
4. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Neuner EA; Yeh JY; Hall GS; Sekeres J; Endimiani A; Bonomo RA; Shrestha NK; Fraser TG; van Duin D
Diagn Microbiol Infect Dis; 2011 Apr; 69(4):357-62. PubMed ID: 21396529
[TBL] [Abstract][Full Text] [Related]
5. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
6. Changing Characteristics and
Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
[TBL] [Abstract][Full Text] [Related]
7. Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.
Papadimitriou-Olivgeris M; Bartzavali C; Spyropoulou A; Lambropoulou A; Sioulas N; Vamvakopoulou S; Karpetas G; Spiliopoulou I; Vrettos T; Anastassiou ED; Fligou F; Christofidou M; Marangos M
Diagn Microbiol Infect Dis; 2018 Nov; 92(3):235-240. PubMed ID: 30076041
[TBL] [Abstract][Full Text] [Related]
8. Hospital Outbreak of a Colistin-Resistant, NDM-1- and OXA-48-Producing Klebsiella pneumoniae: High Mortality from Pandrug Resistance.
Guducuoglu H; Gursoy NC; Yakupogullari Y; Parlak M; Karasin G; Sunnetcioglu M; Otlu B
Microb Drug Resist; 2018 Sep; 24(7):966-972. PubMed ID: 29265963
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Demirlenk YM; Gücer LS; Uçku D; Tanrıöver C; Akyol M; Kalay Z; Barçın E; Akcan RE; Can F; Gönen M; Ergönül Ö
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):761-769. PubMed ID: 35303195
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
Medeiros GS; Rigatto MH; Falci DR; Zavascki AP
Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
14. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area.
Cristina ML; Alicino C; Sartini M; Faccio V; Spagnolo AM; Bono VD; Cassola G; De Mite AM; Crisalli MP; Ottria G; Schinca E; Pinto GL; Bottaro LC; Viscoli C; Orsi A; Giacobbe DR; Icardi G;
J Infect Public Health; 2018; 11(2):171-177. PubMed ID: 28668656
[TBL] [Abstract][Full Text] [Related]
16. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.
Papadimitriou-Olivgeris M; Marangos M; Christofidou M; Fligou F; Bartzavali C; Panteli ES; Vamvakopoulou S; Filos KS; Anastassiou ED
Scand J Infect Dis; 2014 Sep; 46(9):642-8. PubMed ID: 25017796
[TBL] [Abstract][Full Text] [Related]
18. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
[TBL] [Abstract][Full Text] [Related]
20. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience.
Veeraraghavan B; Shankar C; Karunasree S; Kumari S; Ravi R; Ralph R
Pathog Glob Health; 2017 Jul; 111(5):240-246. PubMed ID: 28670975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
